Accelerating growth

During our last financial year, progress against our strategic objectives included:

• Continued to enhance genetic gain for target traits (including prolificacy, throughput, carcass value and efficiency)
• Expanded use of digital phenotyping to four further sites, helping us identify patterns in movement and behaviour to aid improvement of robustness and longevity
• Added three facilities to our nucleus network, enhancing resilience of supply and expanding capacity in preparation for the marketing of PRRSv-resistant pigs

• Delivered growth across all regions through strong product performance, a robust supply chain and world-class support services
• Increased our share of damline and sireline business with producers across North America, contributing to a 9% rise in operating profit
• Continued to invest in our team, services and supply chain in China, enabling us to increase operating profit by 32% despite challenging market conditions
• Maintained momentum in Latin America and Europe by strengthening relationships with strategic accounts, enhancing operating profits by 12% and 6% respectively

• Grew royalty volumes in China by 41%, while increasing the proportion of global business covered by royalty contracts to 85%¹
• Increased the volume of boars distributed through our CBV Max programme, in which our most elite genes command a higher price, by 80%
• Commitment to improve the knowledge of our products and to show the economic benefits of using PIC’s genetics was shown through 61 product validation and management trials in 10 countries, involving over 98,000 pigs

_{1 Genus Group (inc Brazil JV)}